Conference Speakers
Cultural Speakers
Cultural practices, beliefs, and norms play a very important role not only in delivering health care to clients and patients, but also in how that health care is received and what outcomes are possible. Diversity within those beliefs and practices, and as a result of available resources or social economic/demographic circumstances, must be fully understood in order for health care professionals to provide the best care possible no matter where they are in the world, or what culture they are practicing within.
At GOLD Perinatal Care, we understand the importance of Culture and Diversity in health care, and we are working hard to bring you speakers and presentations from around the world that will help you understand the patients and clients you are working with. Discovering how health care is provided and received in other countries and cultures around the world can have a positive impact on our own professional practice. Given that culture is defined by much more than political borders, GOLD Perinatal Care invites speakers to share their knowledge and expertise about perinatal health care from a geographically-based focus or a people-group focus from within a particular set of beliefs, lifestyle or minority. This year, our Culture and Diversity speakers will be presenting on:
X
Dr. Speakers Full Name
Speaker Credentials
Annet Mulder first became interested in breastfeeding in the year 2000, when she became a mother for the first time. During and because of her own breastfeeding experiences, in 2002 she became a volunteer with the Dutch breastfeeding Organization and in 2008 sat for and passed the exam administered by the International Board of Lactation Consultant Examiners. As an International Board Certified Lactation Consultant, she now
Annet Mulder first became interested in breastfeeding in the year 2000, when she became a mother for the first time. During and because of her own breastfeeding experiences, in 2002 she became a volunteer with the Dutch breastfeeding Organization text text text text more name mulder first became interested in breastfeeding in the year 2000, when she became.
X
Abstract: Breastfeeding mothers may turn to formula and/or bottles for many
reasons. Some supplementing with formula by bottle when they reach out for help, and for some moms,
supplementing by alternative methods may be very overwhelming. Some moms need or choose a combination
of breast milk and formula and others may decide to give occasional or regular bottles of expressed
milk. Whatever the reason, as health care professionals helping a mother to breastfeed, it is our
job to be able to help her to reach her own personal goals even when she needs, or chooses to use,
bottles or formula. Learn about baby-led bottle feeding and why it's so important, different types
of formula, their uses and how to prepare them, and how this all fits in with the WHO code and our
code of professional conduct.
View Full Presentation Information & Scheduling
Dr. Speakers Full Name
Speaker Credentials
Speakers (5191)
An oncology physician focused on the researches about Lung cancer
Published in
Speakers
2001 Graduate of Nara Medical University, M.D. degree
2001-2003 Resident in Second Department of Internal Medicine, Nara Medical University Hospital
2004-2006 Research Staff, Pharmacology Division, National Cancer Center
2008- Assistant Professor, Dept Medical Oncology, Kindai University School of Medicine
Published in
Speakers
Professor, Tongji University School of Medicine Cancer Institute & Director, Department of Medical Oncology, Shanghai Pulmonary Hospital
Published in
Speakers
James Chih-Hsin Yang, MD, PhD, received his MD from National Taiwan University (NTU) in Taipei in 1986 and completed his PhD degree between 1996 and 2000 at the Graduate Institute of Clinical Medicine, NTU, in 2000. He first completed his internal medicine residency at the NTU Hospital, and between 1992 and 1995, he undertook medical oncology fellowship training at the National Cancer Institute at Bethesda, Maryland. He is currently the director and distinguished professor of the Graduate Institute of Oncology at National Taiwan University. He is also the director of the Department of Oncology at the National Taiwan University Hospital. He has been a staff member in the Department of Oncology at the University Hospital since 1995.
Dr Yang’s research focuses on lung cancer treatment and the mechanism of resistance of chemotherapy, targeted therapy and immunotherapy. Dr Yang is a leader in lung cancer clinical studies, especially in the new drug development for lung cancer treatment. He and other Asian investigators have established EGFR TKI as the front-line treatment for lung cancer patients with EGFR mutation (IPASS). He is also the principal investigator of several studies that led to the global approval of the 2nd-generation irreversible EGFR TKI, afatinib, and the 3rd-generation EGFR TKI, osimertinib. He has published more than 250 papers in peer-reviewed scientific journals such as New England Journal of Medicine, Lancet Oncology, and Journal of Clinical Oncology, and has served on the editorial board of Annals of Oncology and Lung Cancer. He is the current associate editor of Journal of Thoracic Oncology and Nature Scientific Report. He received the 2nd Kobayashi Foundation Cancer Research Award from the Asian Clinical Oncology Society in 2012, the distinguished research award of the Taiwan National Science Council 2012-2015, the TECO award for biotechnology in 2015, distinguished research award of the Ministry of Science and Technology, Taiwan, from 2016-2018 and Academic Award from Taiwan Ministry of Education in 2018. Distinguished chair scholar from the Foundation on 2019-2021. National Chair Scholar from Ministry of Education from 2021-2024. He currently serves on the board of directors of the International Association for the Study of Lung Cancer (IASLC), with an appointment from 2017-2021.
Published in
Speakers
Dr. Tanizaki is a medical oncologist who specializes lung cancer and molecular targeted therapy in Japan. She received MD in 2007 and PhD in 2011 at Kindai University, faculty of medicine, Japan. After having trained as postdoctoral fellow at Dana-Farber Cancer Institute, Dr, Pasi Janne’s lab, from 2012 to 2015, she is back in Japan and is one of the young leaders in Japanese medical oncology society. Her research interests are tyrosine kinase inhibitors and their resistant mechanisms in solid tumors, especially thoracic cancers.
Published in
Speakers
Dr. Se-Hoon Lee is a professor in the Division of Hematology/Oncology at Sungkyunkwan University and is the faculty of Samsung Medical Center. He is a graduate of Seoul National University College of Medicine and completed post-graduate training at Seoul National University College of Medicine. He worked as a visiting scholar at Dana-Farber Cancer Institute and Broad Institute in Boston, which was supervised by Dr. Matthew Meyerson, one of the leader of The Cancer Genome Atlas. Dr. Lee’s area of research and clinical activity have focused on lung cancer. He has authored and co-authored over 300 medical articles on clinical and translational oncology and is involved in dozens of clinical trials related to lung cancer therapy and diagnostics. His research focuses on finding the association of molecular character and clinical outcomes, and new therapeutic strategy through it. In the era of immunotherapy, his research has moved to exploring genomic and transcriptomic features to predict the clinical response to immunotherapy and discover new therapeutic target for it. His recent publications include the association between genomic feature, DNA global methylation and microbiome and response to immune checkpoint inhibitors in lung cancer. Dr. Lee serves as a member of the International Association for the Study of Lung Cancer (IASLC), American Society of Clinical Oncology (ASCO) and American Association of Cancer Research (AACR).
Published in
Speakers
Professional experience:
2000-2003 Rotating internship in the Niigata University Medical and Dental Hospital, Niigata City, Japan
2004-2008 Clinical fellow in Internal Medicine (II), Niigata University Medical and Dental Hospital, Niigata City, Japan
2009-2010 Research resident of Medical Oncology in the Division of Thoracic Oncology, Shizuoka Cancer Center, Sunto-gun, Shizuoka, Japan
2011-2012 Clinical fellow in Internal Medicine (II), Niigata University Medical and Dental Hospital, Niigata City, Japan
2013-2014 Assistant Professor in Advanced Disaster Medical and Emergency Critical Center, Niigata University Medical and Dental Hospital, Niigata City, Japan
2015 Medical Doctor in Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata City, Japan
2016-Present Chief physician in Department of Internal Medicine, Niigata Cancer Center Hospital, Niigata City, Japan
Published in
Speakers
Member of NSCLC Expert Committee of CSCO
Member of Sarcoma Expert Committee of CSCO
Member of the Youth Expert Committee of CSCO
Member of Immunotherapy Expert Committee of CSCO
Vice chairman of the National Committee of Young Experts on Clinical Application and Monitoring of Antineoplastic Drugs
Standing member of Lung Cancer Committee of China Primary Health Care Foundation
Standing Member of Professional Committee on Lung Cancer of Beijing Oncology Society
Standing Member of Lung Cancer Immunotherapy Committee of Beijing Cancer Prevention and Control Society
Member of Youth Committee of Oncology Society of Beijing Medical Association
Key Members of the Innovation Team of the Ministry of Education
Won the “National Natural Science Youth Fund”?“National Natural General Project”?“First Prize of Science and Technology Progress of Ministry of Education”,
“Second Prize of National Science and Technology Progress”
Long-term commitment to standardized individualized multidisciplinary comprehensive treatment and transformation of lung cancer-based thoracic tumors
Published in
Speakers
Prof. Zhou studied medicine at NanTong Medical College and got the Ph.D at China Medical University in China. He got a fellow training in Tokyo National Chest Hospital for 2 years and worked as a visiting scientist for half an year at MD Anderson Cancer Center.
In 1998, Prof Zhou moved to Shanghai and got a position as professor and director in the Department of Medical Oncology at Shanghai Pulmonary Hospital. He has more than 30 years of experience in clinical oncology with his main research interests focusing on early detection, molecular targeted therapy, and immunotherapy in lung cancer.
Prof Zhou has published over 200 articles in international peer review journals, including the Lancet Oncology, Lancet Respiratory Medicine and Journal of Clinical Oncology.
He is also involved in several professional societies, including associate editor of IASLC Newsletter, IASLC, chairmen of the NSCLC expert society in Chinese Society of Clinical Oncology (CSCO) and chairman of Thoracic Oncology Society in CPAM. He actively involved in IASLC meetings, including WCLC, APLCC, ELCC etc.
In addition, he is the Editor-in-Chief of the Translation Lung Cancer Research, the Associate Editor of the Lung Cancer and serves on the Editorial Board of several other major oncology journals.
Published in
Speakers
Dr. Tetsuya Mitsudomi joined the Board of Directors of IASLC in 2011 and has served as its board president since 2019. IASLC awarded Dr. Mitsudomi its Mary J. Matthews Pathology/Translational Research Award in 2013 for a lifetime achievement in pathology and translational research of thoracic malignancies.
Dr. Mitsudomi has served as a professor in the Division of Thoracic Surgery at Kindai University Faculty of Medicine in Osaka, Japan since 2012. Prior to his current role, Dr. Mitsudomi worked as Chief of the Department of Thoracic Surgery at Aichi Cancer Center for 16 years after he served as an associate professor and vice director of the Kyushu University Hospital. His research focuses on the surgical treatment of lung cancer and individualized treatment of lung cancer based on cancer genotypes such as EGFR mutations and ALK translocations. He has published more than 400 papers that have been featured in international peer-reviewed journals.
Dr. Mitsudomi earned his medical degree and his Ph.D. at Kyushu University Faculty of Medicine in Fukuoka, Japan. He completed his residency in surgery at Kyushu University Hospital and was a visiting fellow at the National Cancer Institute-Navy Medical Oncology Branch in Bethesda, Maryland from 1989 to 1991.
Published in
Speakers
